National Academies Press: OpenBook

New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986)

Chapter: Appendix A: Selection of Vaccine Candidates for Accelerated Development

« Previous: 9. Findings, Conclusions, and Recommendations
Suggested Citation:"Appendix A: Selection of Vaccine Candidates for Accelerated Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

Appendix A
Selection of Vaccine Candidates for Accelerated Development

JUDGING THE FEASIBILITY OF ACCELERATED VACCINE DEVELOPMENT

The selection of candidates for accelerated vaccine development depends in part on the mechanisms used to promote development. In the broadest sense, accelerated development could refer to any increase in emphasis or funding at any point along the continuum from disease definition and basic research through clinical trials to licensure.

In the early phases of vaccine development, the questions that need to be answered and the methods most appropriate for answering them may be difficult to define. Diverse approaches may be desirable until a scientific consensus emerges on the research directions most likely to be productive. Once the pathways for development have been set, however, the tasks needed to bring the vaccine to licensure are easier to identify and place in a uniform framework.

The National Institute of Allergy and Infectious Diseases’ (NIAID) influence to accelerate development is most likely to be effective in the latter stages of the continuum, probably through the contract mechanism. One of the committee’s first responsibilities was to identify vaccine candidates “ready” for this kind of support. Candidates were included in the ranking exercise described in Chapter 3 if committee members and knowledgeable consultants believed that their successful development was technically possible within 10 years. Candidates excluded from the analysis are described briefly in the supplement to this volume (see Appendix I), or in the committee’s first report (Appendix B, Institute of Medicine, 1985).

The knowledge required to determine the feasibility of accelerated development covers a wide spectrum, from characteristics of the pathogen to the composition of the target population. The latter is important not only for cost-effective vaccine delivery, but also to determine whether there is sufficient motivation to achieve reasonable utilization. No checklist can replace experienced judgment in assessing vaccine feasibility, but it is possible to identify certain factors that generally facilitate vaccine development (although all may not be essential):

Suggested Citation:"Appendix A: Selection of Vaccine Candidates for Accelerated Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
  • knowledge of clinical signs and symptoms of the disease to allow differentiation from similar syndromes

  • identification of the pathogen and its major characteristics, including strains and serotypes, their infectivity, their virulence, their antigenicity, and the nature of essential immunogens

  • the existence of specific techniques for cultivation of the pathogen

  • identification of nonhuman models of infection

  • knowledge of the human immune response to the pathogen, including the duration and type of response (e.g., serum antibody, mucosal antibody, or cell-mediated immunity)

  • definition of the target population.

All aspects of the knowledge base that involve technical feasibility must be reassessed frequently: a vaccine not foreseeable today may become a reality in the future because of one unexpected development in the laboratory. Such developments are especially likely in the fields relevant to vaccine development because modern biotechnology has only begun to be explored.

ACCELERATED VACCINE DEVELOPMENT AND BASIC RESEARCH PRIORITIES

The criteria for selecting candidates for accelerated vaccine development do not address the general question of which vaccines are most needed in the developing world or its particular regions. For some diseases that impose major burdens, the knowledge base is insufficient to allow consideration of accelerated vaccine development by NIAID. Nevertheless, portions of the analysis described in this report can be applied to these disease problems to gain useful information about long-term goals and potential benefits. The description of disease burden considerations in Chapter 4 may be especially helpful in this regard.

The committee hopes that the selection of candidates for accelerated vaccine development will not divert funds from long-term basic research programs. For these programs, the scientific merit of the research proposal should continue to be the dominant criterion for funding.

SELECTING CANDIDATES FOR ACCELERATED DEVELOPMENT

The committee believed that its major contribution to establishing priorities would be the clear explication of a logical method for this task and that it probably could never satisfy all potential critics with its choice of candidates for assessment. As noted in Chapter 3, if a candidate is omitted from the full assessment, no conclusions should be made regarding its position in the priority rankings relative to the assessed contenders. When the prospects for vaccine control of disease were reasonable, however, the committee tried to include in the full analysis those candidates generally recognized in the developing world and the United States as major disease problems.

Suggested Citation:"Appendix A: Selection of Vaccine Candidates for Accelerated Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

The process involved a number of iterations of selection, review, and revision. At an international workshop in Washington, D.C., on August 1–3, 1984, a draft list of infectious diseases prevalent in the developing world was reviewed and revised. This list was the starting point for candidate selection and is shown in Table A.1.

About 40 diseases were chosen from Table A.1 by the workshop participants as major health problems in the developing world. These diseases are listed in Table A.2. Some diseases were included in this list as models because vaccine prospects had been carefully reviewed in the committee’s prior assessment.

A working group at the workshop then assessed the state of knowledge on these diseases in three areas: disease mechanisms, protective mechanisms, and protective antigens. A simple scoring system was used (+/++/+++), and on the basis of scores, pathogen/disease entities were assigned to one of three categories: good prospects for the technical feasibility of vaccine development, promising prospects, or insufficient knowledge to evaluate prospects. Based on these judgments, candidates were either included in the full assessment, excluded from it, or subjected to further review by a committee subgroup which consulted with experts on relevant vaccine development efforts.

Appendixes D-1 through D-19 describe the prospects for immunizing against the candidate pathogens, and the supplement to this volume describes prospects and knowledge gaps for a range of diseases prevalent in the developing world and for which accelerated development efforts are not feasible or appropriate at this time.

For a number of the pathogens considered in the supplement, vaccine development prospects are such that their exclusion from consideration was a difficult decision. Because of rapid technologic advances in the vaccine development field, the state of knowledge and vaccine development prospects for these potential candidates should be regularly reviewed.

Table A.3 lists the pathogens for which the vaccine development prospects were reviewed in the committee’s first report. For various reasons, these pathogens were not included as primary contenders in the assessment of vaccine priorities for important diseases in the United States, although some are now included in this analysis.

REFERENCE

Institute of Medicine. 1985. New Vaccine Development: Establishing Priorities, Volume I. Diseases of Importance in the United States. Washington, D.C.: National Academy Press.

Suggested Citation:"Appendix A: Selection of Vaccine Candidates for Accelerated Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

TABLE A.1 Important Diseases in Developing Countries

Amebiasis

E. histolytica

Ancylostomiasis (hookworm disease)

N. americanus

A. duodenale

A. ceylanicum

Ascariasis

A. lumbricoides

Brucellosis

B. abortus, biotypes 1–9

B. canis

B. melitensis, biotypes 1–3

B. suis, biotypes 1–4

Chlamydial infections (see also trachoma)

Chlamydia

Cholera

V. cholerae

Cryptosporidiosis

Cryptosporida spp.

Cytomegalovirus

Dengue fever

Immunological types 1–4

Group B togaviruses

Dengue hemorrhagic fever

Diarrheas, viral

Norwalk agent

Rotaviruses

Diarrheas, bacterial

Enteropathic E. coli

Enterotoxigenic E. coli

C. jejuni

Salmonella (nontyphoid)

Shigella

Herpes simplex virus

Herpesvirus varicellae

Japanese encephalitis

Leishmaniasis, cutaneous

Old world, L. tropica

New world, L. brasiliensis and L. mexicana

Leishmaniasis, visceral

L. donovani

Leprosy

M. leprae

Malaria

P. vivax

P. malariae

P. falciparum

P. ovale

Measles (rubeola)

Measles virus

Meningitis, aseptic

Enteroviruses (picornaviruses)

Coxsackie virus group A, types 2, 3, 7, 9

Coxsackie virus group B, types 2–5

Echovirus types 2, 5–7, 9–11, 14, 18, 30

Poliovirus

Arboviruses

Mumps

H. simplex and varicella viruses

Adenovirus

Meningitis, meningococcal

N. meningitidis

Mumps

Mumps virus, a myxovirus

Onchocerciasis (skin disease and river blindness), O. volvulus

Respiratory infections, acute bacterial

B. pertussis

S. pneumoniae

M. pneumoniae

H. influenzae

L. pneumophilia

Rift Valley fever

Rift Valley fever virus (group B togavirus)

Rubella

Rubella virus

Russian spring-summer encephalitis

Group B togavirus

Salmonellosis

S. typhimurium

S. heidelberq

S. newport

S. infantis

S. enteritidis

S. st. paul

Schistosomiasis

S. mansoni

S. haematobium

S. japonicum

S. intercalatum

Shigellosis

S. dysenteriae, group A

S. flexneri, group B

S. boydii, group C

S. sonnei, group D

Streptococcus group A

Streptococcus group B

Syphilis

T. pallidum

Suggested Citation:"Appendix A: Selection of Vaccine Candidates for Accelerated Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

Diarrheas, parasitic

E. histolytica

G. lamblia

Diphtheria

C. diphtheriae

Dracunculiasis (Guinea worm disease)

Eastern equine encephalitis

Epstein-Barr virus

Filariasis

W. bancrofti

B. malayi

Giardiasis

G. lamblia

Gonorrhea

N. gonorrhoeae

Hantaan viruses and related agents

Hepatitis A

Hepatitis B

Hepatitis non-A, non-B

Paratyphoid fever

S. paratyphi A (S. enteritidis serotype paratyphoid A)

S. schottmuelleri (S. paratyphi B, S. enteritidis serotype paratyphoid B)

S. paratyphi C (S. hirschfeldii, S. enteritidis serotype paratyphoid C)

Plague

Y. pestis (P. pestis)

Poliomyelitis

Poliovirus types 1, 2, 3

Q fever

C. burneti (R. burneti)

Rabies

Rabiesvirus, a rhabdovirus

Relapsing fever

B. recurrentis

Respiratory infections, acute viral

Parainfluenza types 1–4

Respiratory syncytial virus

Adenovirus, types 1–7, 14, 21

Rhinoviruses

Coronaviruses

Types of coxsackie virus groups A and B

Echoviruses

Tetanus

C. tetani

Trachoma

C. trachomatis

Trichuriasis

T. trichiura (T. trichiurus)

Trypanosomiasis, African

T. gambiense

T. rhodensiense

Trypanosomiasis, South American

T. cruzi

Tuberculosis

M. tuberculosis

Typhoid

S. typhi

Typhus

Rickettsia

West Nile fever

West Nile fever virus (group B togavirus)

Suggested Citation:"Appendix A: Selection of Vaccine Candidates for Accelerated Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×

TABLE A.2 Potential Candidate Diseases for New or Improved Vaccine Development

Amebiasis

Ancylostomiasis (hookworm)

Ascariasis

Brucellosis

Chlamydial infections

Cholera

Dengue fever

Diarrheas

E. coli

Norwalk agent

Salmonella (nontyphoid)

Shigella

Rotavirus

Campylobacter

Filariasis

Giardiasis

Gonorrhea

Hantaan virus

Hemophilus influenzae type B

invasive disease

Hepatitis A

Hepatitis B

Influenza virus

Japanese encephalitis

Leishmaniasis

Leprosy

Malaria

Measles

Meningococcal meningitis

Onchocerciasis

Skin disease

River blindness

Pertussis

Rabies

Respiratory infections

Parainfluenza

Respiratory syncytial virus

Adenovirus

Streptococcus pneumoniae

Hemophilus influenzae

Schistosomiasis

Streptococcus group A

Streptococcus group B

Trichuriasis

Trypanosomiasis

African

South American

Tuberculosis

Typhoid

Yellow fever

TABLE A.3 Pathogens Not Included as Candidates but Discussed in the Committee’s First Report (Appendix B)

Acquired immune deficiency syndrome agent

Adenovirus (respiratory disease)

Anaerobic bacteria

Clostridium botulinum

Clostridium difficile

Clostridium perfringens

Clostridium tetani

Chlamydia

Epstein-Barr virus

Giardia lamblia

Hospital acquired infections (gram-negative bacteria)

Nontypable Hemophilus influenzae

Non-A, non-B hepatitis

Histoplasma capsulatum

Human papilloma virus

Kawasaki disease agent

Legionella spp. (Legionnaire’s disease)

Mycoplasma pneumoniae

Rhinovirus

Rickettsia rickettsii (Rocky Mountain spotted fever)

Salmonella spp. (nontyphoidal)

Staphylococcus aureus

Streptococcus mutans

Treponema pallidum (syphilis)

Treponema-like spirochete of Lyme disease

Suggested Citation:"Appendix A: Selection of Vaccine Candidates for Accelerated Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page 143
Suggested Citation:"Appendix A: Selection of Vaccine Candidates for Accelerated Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page 144
Suggested Citation:"Appendix A: Selection of Vaccine Candidates for Accelerated Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page 145
Suggested Citation:"Appendix A: Selection of Vaccine Candidates for Accelerated Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page 146
Suggested Citation:"Appendix A: Selection of Vaccine Candidates for Accelerated Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page 147
Suggested Citation:"Appendix A: Selection of Vaccine Candidates for Accelerated Development." Institute of Medicine. 1986. New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press. doi: 10.17226/920.
×
Page 148
Next: Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness »
New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries Get This Book
×
Buy Paperback | $65.00
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Common diseases cost the developing world an enormous amount in terms of human life, health, and productivity, as well as lost economic potential. New and effective vaccines could not only improve the quality of life for millions of residents in developing countries, they could also contribute substantially to further economic development. Using data from the World Health Organization and other international agencies, this book analyzes disease burdens, pathogen descriptions, geographic distribution of diseases, probable vaccine target populations, alternative control measures and treatments, and future prospects for vaccine development. New Vaccine Development provides valuable insight into immunological and international health policy priorities.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!